|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
3
|
|
gptkbp:bfsParent
|
gptkb:drug
|
|
gptkbp:approves
|
gptkb:1990
|
|
gptkbp:brand
|
gptkb:Methylphenidate
|
|
gptkbp:category
|
gptkb:C
|
|
gptkbp:clinical_trial
|
cognitive function
behavioral assessment
long-term safety
ADHD treatment
|
|
gptkbp:contraindication
|
gptkb:sneaker
tics
history of drug abuse
severe anxiety
|
|
gptkbp:dosage_form
|
extended-release tablet
|
|
gptkbp:environmental_impact
|
moderate
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:form
|
gptkb:tablet
oral solution
chewable tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Methylin
|
|
gptkbp:ingredients
|
gptkb:drug
C14 H19 N O2
|
|
gptkbp:interacts_with
|
antidepressants
MAO inhibitors
antihypertensives
anticonvulsants
|
|
gptkbp:is_atype_of
|
N06 B A04
|
|
gptkbp:is_used_for
|
attention deficit hyperactivity disorder
|
|
gptkbp:legal_issue
|
prescription only
|
|
gptkbp:lifespan
|
2 to 4 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:UCB,_Inc.
|
|
gptkbp:marketed_as
|
gptkb:Australia
gptkb:United_Kingdom
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:population
|
gptkb:Person
adults
adolescents
|
|
gptkbp:related_to
|
gptkb:Ritalin
|
|
gptkbp:research_focus
|
drug interactions
neuropharmacology
ADHD management
side effect profile
|
|
gptkbp:side_effect
|
anxiety
nausea
insomnia
loss of appetite
|
|
gptkbp:type_of
|
298-00-0
|
|
gptkbp:type_of_care
|
improved with extended-release
|